| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | -0.0023 | 0.9 |